Hironori Takahashi Satoru Inoda Hidenori Takahashi Ryota Takahashi Yuto Hashimoto Hana Yoshida Hidetoshi Kawashima Yasuo Yanagi
Scientific reports 14(1) 9087-9087 2024年4月
This single-center retrospective cohort study analyzed the 1-year real-world treatment outcomes of 63 consecutive eyes (of 60 patients) with neovascular age-related macular degeneration (nAMD) that were switched from intravitreal brolucizumab (IVB...
Takuya Takayama Satoru Inoda Hidenori Takahashi Rika Tsukii Hana Yoshida Yuka Kasuya Kosuke Nagaoka Ryota Takahashi Yusuke Arai Hidetoshi Kawashima
Journal of medical case reports 18(1) 80-80 2024年2月
BACKGROUND: This study reports the first cases of scleritis following intravitreal brolucizumab (IVBr) injection for nAMD, emphasizing the need to be aware of the possibility of scleritis following IVBr injections. CASE PRESENTATION: Case 1. A 74-...
Satoru Inoda Hidenori Takahashi Ryota Takahashi Yuto Hashimoto Hana Yoshida Rika Tsukii Hironori Takahashi Hidetoshi Kawashima Yasuo Yanagi
Scientific reports 14(1) 2451-2451 2024年1月
A new anti-vascular endothelial growth factor agent, brolucizumab, was approved by the United States Food and Drug Administration in 2019. We evaluated whether brolucizumab reduces the treatment burden of neovascular age-related macular degenerati...
PURPOSE: To identify factors associated with intraocular inflammation (IOI) in patients with neovascular age-related macular degeneration (nAMD) treated with brolucizumab. METHODS: In this prospective observational study, we collected aqueous humo...
自治医科大学
医学部